FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy – OncLive
OncLive |
FT819 Derives Renewable, Reproducible Process of CAR T-Cell Therapy
OncLive An off-the-shelf, dual-targeted chimeric antigen receptor (CAR) T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies, according to findings presented at the 2018 AACR Annual Meeting. FT819 … Findings With FT819 Demonstrate Promising, Accessible Approach to CAR T-Cell Therapy |
